Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Akash R. Boda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6250-0498; OpenAlex author ID A5049798968. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

  1. IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. Co-author DOI 10.1038/s41598-026-42259-8↗
  2. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. Co-author DOI 10.1172/jci.insight.169150↗
  3. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. First author DOI 10.1136/jitc-2021-003246↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael A. Curran · 3 shared papers, 2021–2026 · strength 0.61
  2. Casey R. Ager · 2 shared papers, 2021–2024 · strength 0.34
  3. Manisha Singh · 1 shared paper, 2026 · strength 0.27
  4. Saikat Chowdhury · 1 shared paper, 2026 · strength 0.27
  5. Jason Roszik · 1 shared paper, 2026 · strength 0.27
  6. Scott Kopetz · 1 shared paper, 2026 · strength 0.27
  7. David R Piwnica-Worms · 1 shared paper, 2024 · strength 0.23
  8. Arthur J. Liu · 1 shared paper, 2024 · strength 0.23
  9. David S. Hong · 1 shared paper, 2024 · strength 0.23
  10. Rishika Prasad · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.